BCAX
BCAX
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
1
$4.80M
Insider Sales
44
$14.91M
Total Volume
$19.71M
80 transactions
Net Activity
$10.11M
Net selling
Sentiment Rating
Moderate DistributionCEO Conviction Index
Liquidating / Profit Taking
Key Drivers
- •Heavy distribution: sales represent 76% of total transaction value.
- •CEO selling activity detected. Often driven by option expiration or diversification plans.
- •High accumulation: total purchase value exceeds $1M.
- •Significant liquidation: total sale value exceeds $10M.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
Multiple Insiders
S - Sale+OE Insiders
$2176.80B total
Ra Capital Management, L.P.
Dir, 10%
$4.80M total
Cohlhepp Ryan
Pres, COO, Interim CEO
$4.60M total
Mazumdar Claire
CEO
$4.06M total
Hyep Ivan
CFO
$3.24M total
Quick Actions
BCAX has an insider buy conviction of 24%, compared to the Unknown sector buy average of 6%.
Over the last 90 days, corporate insiders at BCAX (BCAX) engaged in a total of 80 transactions reported via SEC Form 4 filings. Among these, 1 were open-market purchases and 44 were sales. The total volume of insider trading reached $19.71M.
The net insider activity for BCAX shows a net selling bias of $10.11M. This activity represents a 24% buy ratio, suggesting that insiders are currently bearish on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Multiple Insiders (P - Purchase Insiders), who traded 7.26M shares valued at $2176.80B on Feb 26, 2026.
Bicara Therapeutics (BCAX) Stock Gets Fair Value Trim As Analysts Split On Ficera
BCAX Stock Price and Chart — NASDAQ:BCAX
$BCAX stock is down 35% today. Here's what we see in our data.
Behavioral Patterns of BCAX and Institutional Flows
BCAX - Bicara Therapeutics Inc Stock Price and Quote
Bicara Therapeutics (BCAX) Stock May Look Overvalued On Book Value
FAQs About BCAX Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for BCAX.